Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bazedoxifene + cholecalciferol is a fixed-dose combination of two active ingredients: bazedoxifene, a third-generation selective estrogen receptor modulator (SERM), and cholecalciferol, also known as vitamin D3. Bazedoxifene acts as an estrogen receptor agonist or antagonist depending on the tissue type, decreasing bone resorption and increasing bone mineral density by reducing biochemical markers of bone turnover. Cholecalciferol is a form of vitamin D that helps regulate calcium and phosphate homeostasis, supporting healthy bone formation. This combination is being developed primarily for the treatment and prevention of postmenopausal osteoporosis[8][5][3]. The product has been studied in clinical trials for its pharmacokinetics and tolerability in healthy volunteers[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bazedoxifene + cholecalciferol.